Latest On UCB SA (UCBJF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2024-04-26 05:59 EST | Dividend | A dividend of $1.36 has been announced on Feb 28, 2024. It will be paid Apr 30, 2024 with an ex-dividend date of Apr 26, 2024. | Neutral |  |
| 2023-05-01 05:58 EST | Dividend | A dividend of $1.33 has been announced on Feb 22, 2023. It will be paid May 3, 2023 with an ex-dividend date of May 1, 2023. | Neutral | |
| 2022-11-11 02:45 EST | News | UCB touts positive late-stage data for bimekizumab in several indications | N/A | |
| 2022-04-29 05:58 EST | Dividend | A dividend of $1.3 has been announced on Apr 22, 2022. It will be paid May 3, 2022 with an ex-dividend date of Apr 29, 2022. | Neutral | |
| 2022-02-25 01:01 EST | News | UCB SA Non-GAAP EPS of €6.49, revenue of €5.78B | N/A | |
| 2021-04-30 06:01 EST | Dividend | A dividend of $1.27 has been announced on Nov 30, -0001. It will be paid May 4, 2021 with an ex-dividend date of Apr 30, 2021. | Neutral | |
| 2021-02-26 16:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-26 22:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-13 15:53 EST | News | European advisory group backs new uses of six medicines | N/A | |
| 2020-11-12 11:18 EST | News | UCB boosts gene therapy footprint with two new deals | N/A | |
| 2020-11-08 01:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 18:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 15:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 07:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 11:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 14:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 10:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 10:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 18:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 10:07 EST | News | UCB out-licenses Alzheimer's candidate to Roche | N/A | |
| 2020-07-30 06:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 22:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 14:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 11:39 EST | News | UCB SA reports 1H results | N/A | |
| 2020-07-23 19:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 10:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-07 23:49 EST | News | UCB teams up with Ferring Pharma to commercialize prefilled syringe Cimzia | N/A | |
| 2020-07-01 18:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 02:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 14:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 06:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 08:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-06 00:51 EST | News | UCB acquires Engage Therapeutics for up to $270M | N/A | |
| 2020-05-27 07:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 02:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 07:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-04 06:07 EST | Dividend | A dividend of $1.24 has been announced on N/A. It will be paid May 6, 2020 with an ex-dividend date of May 4, 2020. | Neutral | |
| 2020-05-01 18:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-20 06:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-17 00:19 EST | News | Amgen, Jazz Pharma most exposed to recession risk - Bernstein | N/A | |
| 2020-04-14 13:43 EST | News | UCB SA reports FY results | N/A | |
| 2020-04-14 13:40 EST | News | UCB to divest lineup of alprostadil products to Advanz Pharma for $84M | N/A | |
| 2020-04-03 22:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-25 22:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 05:51 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-27 23:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-24 00:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-22 01:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-21 00:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-18 01:14 EST | Financials | Company financials have been released. | Neutral | |
About UCB SA (UCBJF):
UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, nayzilam, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; bimekizumab for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition , the company is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis immune-mediated necrotizing myopathy; staccato alprazolam to treat active epileptic seizure; and UCB0107 to treat tauopathies and progressive supranuclear palsy. Further, it engages in contract manufacturing activities. The company has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was founded in 1928 and is headquartered in Brussels, Belgium.
General
- Name UCB SA
- Symbol UCBJF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 7,820
- Fiscal Year EndDecember
- Web URLhttp://www.ucb.com
View More
Valuation
- Trailing PE 17.62
- Forward PE 13.93
- Price/Sales (Trailing 12 Mt.) 1.45
- Price/Book (Most Recent Quarter) 2.07
- Enterprise Value Revenue 3.61
- Enterprise Value EBITDA 14.84
View More
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 14%
- Return on Assets 6%
- Return on Equity 11%
- Earnings Per Share $5.40
- Revenue Per Share $0
- Gross Profit 3.98 billion
- Quarterly Earnings Growth 12.3%
View More
ESG Rating
Highlights
- Market Capitalization 17.69 billion
- PEG Ratio 12.72
- Book Value Per Share $37.14
View More
Share Statistics
- Shares Outstanding 189.02 million
- Shares Float 120.95 million
- % Held by Insiders 3500%
- % Held by Institutions 37.91%
View More
Technicals
- Beta 0.39
- 52 Week High $131
- 52 Week Low $67.91
- 50 Day Moving Average 103.22
- 200 Day Moving Average 108.77
View More
Dividends
- Forward Annual Dividend Rate $1.34
- Forward Annual Dividend Yield 1.41%
- Payout Ratio 41%
- Dividend Date 2017-05-03
- ExDividend Date 2020-05-04
- Dividend Per Share $1.38
- Dividend Yield 0%
View More
UCB SA (UCBJF) Dividend Calendar:
UCBJF's last dividend payment was made to shareholders on May 3, 2017.
UCB SA pays out 41% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
UCB SA (UCBJF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $N/A | $1.13 | $0.00 | |
| 2020-06-30 | 2020-09-30 | $N/A | $1.09 | $0.00 | |
| 2020-03-31 | 2020-06-30 | $N/A | $1.08 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $1.3 billion | $1.06 | $0.00 | |
| 2019-03-31 | 2019-06-30 | $1.16 billion | $1.25 | $0.00 | |
| 2018-12-31 | 2019-03-31 | $N/A | $1.23 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $1.13 billion | $1.71 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $331.4 million | $1.80 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $325.09 million | $1.02 | $0.00 | |
| 2017-06-30 | 2017-09-30 | $1.24 billion | $1.00 | $0.00 | |
| 2017-03-31 | 2017-06-30 | $1.16 billion | $1.31 | $0.00 | |
| 2016-12-31 | 2017-03-31 | $N/A | $1.22 | $0.00 | |
| 2016-09-30 | 2016-12-31 | $N/A | $0.65 | $0.00 | |
| 2016-06-30 | 2016-09-30 | $0.70 | $0.00 | ||
| 2016-03-31 | 2016-06-30 | $0.91 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | $0.93 | $0.00 | ||
| 2015-09-30 | 2015-12-31 | $0.07 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | $0.07 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | $0.69 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | $0.67 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | $0.09 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | $0.09 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | $0.31 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | $0.31 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | $0.08 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | $0.08 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | $0.20 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | $0.20 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | $0.48 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | $0.47 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | $0.10 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | $0.10 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | $0.76 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | $0.74 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | -$0.20 | $0.00 |
UCB SA (UCBJF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
UCB SA (UCBJF) Chart:
UCB SA (UCBJF) News:
Below you will find a list of latest news for UCB SA (UCBJF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
UCB SA (UCBJF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
UCB SA (UCBJF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2005-03-01 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1290640/000090342305000183/0000903423-05-000183-index.htm |
| 2005-03-08 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1290640/000090342305000194/0000903423-05-000194-index.htm |
| 2006-10-17 | 144 | Report of proposed sale of securities | https://www.sec.gov/Archives/edgar/data/1290640/000090342306001136/0000903423-06-001136-index.htm |
| 2006-10-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1290640/000090342306001189/0000903423-06-001189-index.htm |
| 2006-10-31 | 144/A | Report of proposed sale of securities | https://www.sec.gov/Archives/edgar/data/1290640/000090342306001190/0000903423-06-001190-index.htm |
| 2006-11-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1290640/000090342306001195/0000903423-06-001195-index.htm |
| 2006-11-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1290640/000090342306001206/0000903423-06-001206-index.htm |
| 2006-11-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1290640/000090342306001215/0000903423-06-001215-index.htm |
| 2006-11-08 | 144/A | Report of proposed sale of securities | https://www.sec.gov/Archives/edgar/data/1290640/000090342306001216/0000903423-06-001216-index.htm |
| 2007-03-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1290640/000090342307000277/0000903423-07-000277-index.htm |
| 2007-03-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1290640/000090342307000278/0000903423-07-000278-index.htm |
| 2008-10-14 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1290640/000101915508000385/0001019155-08-000385-index.htm |
| 2009-02-05 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1290640/000101915509000177/0001019155-09-000177-index.htm |
| 2004-06-10 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1290640/000104746904020115/0001047469-04-020115-index.htm |
| 2004-06-14 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1290640/000104746904020328/0001047469-04-020328-index.htm |
| 2004-06-14 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1290640/000104746904020333/0001047469-04-020333-index.htm |
| 2004-06-15 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1290640/000104746904020472/0001047469-04-020472-index.htm |
| 2004-06-18 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1290640/000104746904021075/0001047469-04-021075-index.htm |
| 2004-06-24 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1290640/000104746904021625/0001047469-04-021625-index.htm |
| 2004-07-02 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1290640/000104746904022436/0001047469-04-022436-index.htm |
| 2004-07-06 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1290640/000104746904022577/0001047469-04-022577-index.htm |
| 2004-07-07 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1290640/000104746904022704/0001047469-04-022704-index.htm |
| 2004-07-09 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1290640/000104746904022949/0001047469-04-022949-index.htm |
| 2004-07-12 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1290640/000104746904023050/0001047469-04-023050-index.htm |
| 2004-07-14 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1290640/000104746904023284/0001047469-04-023284-index.htm |
| 2004-08-11 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1290640/000104746904026094/0001047469-04-026094-index.htm |
| 2004-08-25 | SC TO-T/A | Tender offer statement by Third Party | https://www.sec.gov/Archives/edgar/data/1290640/000104746904027262/0001047469-04-027262-index.htm |
| 2009-01-09 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1290640/000114420409001174/0001144204-09-001174-index.htm |
| 2015-12-03 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1290640/000119312515394286/0001193125-15-394286-index.htm |
| 2016-12-21 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1290640/000119312516800558/0001193125-16-800558-index.htm |
| 2017-03-17 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1290640/000119312517087041/0001193125-17-087041-index.htm |
| 2013-07-03 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1290640/000119380513001224/0001193805-13-001224-index.htm |
| 2014-06-17 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1290640/000119380514001237/0001193805-14-001237-index.htm |
| 2017-09-29 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1290640/000119380517002512/0001193805-17-002512-index.htm |
| 2019-11-22 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1290640/000119380519001605/0001193805-19-001605-index.htm |
| 2015-05-13 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1290640/000129064015000004/0001290640-15-000004-index.htm |
| 2014-10-31 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1290640/000157104914005648/0001571049-14-005648-index.htm |
| 2008-04-02 | 12G3-2B | Exemptions for American Depository Receipts and Certain Foreign Securities | https://www.sec.gov/Archives/edgar/data/1290640/999999999708023701/9999999997-08-023701-index.htm |
| 2008-04-02 | ARS | Annual Report to Security Holders | https://www.sec.gov/Archives/edgar/data/1290640/999999999708023702/9999999997-08-023702-index.htm |
| 2008-04-02 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1290640/999999999708023703/9999999997-08-023703-index.htm |